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448 The Journal of Thoracic and Cardbjective: The aggressiveness of small adenocarcinomas has not been fully evaluated
sing integrated positron emission tomography/computed tomography. We investigated
alignant aggressiveness according to positron emission tomography/computed tomog-
aphy, high-resolution computed tomographic findings, and the proportions of patho-
ogically defined bronchioloalveolar carcinomas in cT1N0M0 lung adenocarcinoma.
ethods: Sixty consecutive patients with cT1N0M0 lung adenocarcinomas of 3 cm or
ess in diameter underwent fluorodeoxyglucose–positron emission tomograph/computed
omography, and high-resolution computed tomography, followed by complete tumor
esection. Correlations between the proportion of bronchioloalveolar carcinoma and
aximum standardized uptake value on positron emission tomographic scan/computed
omographic scan, ground-glass opacity, and tumor shadow disappearance rate were
nvestigated and the findings were compared with clinicopathologic features.
esults: Lymphatic and vascular invasion occurred in 18 (30%) and 13 (22%)
atients, respectively, whereas hilar or mediastinal lymph nodes occurred in 8
atients (13%). Maximum standardized uptake value generally seemed the most
aluable predictor of lymphatic invasion, vascular invasion, and nodal metastasis
ompared with ground-glass opacity, tumor shadow disappearance rate, and bron-
hioloalveolar carcinoma ratios. Although the association was significant between
he bronchioloalveolar carcinoma ratio versus maximum standardized uptake value,
round-glass opacity ratio, and tumor shadow disappearance rate (all P  .0001),
aximum standardized uptake value (R2  0.245) was less correlated with the
ronchioloalveolar carcinoma ratio than was the ground-glass opacity ratio (R2 
.554) and tumor shadow disappearance rate (R2  0.671).
onclusions: The malignant behavior of small adenocarcinomas with a lower maxi-
um standardized uptake value and a greater proportion of ground-glass opacity, tumor
hadow disappearance rate, and bronchioloalveolar carcinoma was less aggressive.
aximum standardized uptake value was a more powerful clinical predictor of biologic
umor performance, independent of pathologic bronchioloalveolar carcinoma propor-
ion. Preoperative assessment of maximum standardized uptake value on positron
mission tomographic/computed tomographic findings, in addition to the ground-glass
pacity ratio and tumor shadow disappearance rate on high-resolution computed tomo-
raphic scans, might be useful to guide treatment strategies for small adenocarcinomas.
ecent improvements in imaging technology and the widespread use of
computed tomographic (CT) scans for screening have increased the proba-
bility of detecting small-sized lung cancers, especially adenocarcinomas,nd this has led to concerns over whether some of these cancers can be sufficiently
iovascular Surgery ● June 2007
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G
TSreated by sublobar resection as an alternative to lobec-
omy.1,2 In fact, about 20% of clinical T1 cancers have
odal involvement and the remainder follows a more indo-
ent biologic course. Because the risk of nodal involvement
nd subsequent systemic metastasis is not absolutely linked
o tumor size,3 the preoperative ability to distinguish bio-
ogically aggressive from indolent tumors is extremely im-
ortant for an indication of sublobar resection.
On high-resolution computed tomographic (HR-CT)
canning, ground-glass opacity (GGO), defined as a misty
omponent in lung attenuation, and tumor shadow disap-
earance rate (TDR), defined as the ratio of tumor area of
he mediastinal window to that of the lung window, seem
inked to adenocarcinoma aggressiveness and thus to the
isk of nodal involvement.4,5 In addition, bronchioloalveolar
arcinomas (BACs) typified by lepidic growth along alveoli
ithout invasive areas are indolent and basically expressed
s GGO or areas of tumor shadow disappearance on
R-CT.
On the other hand, integrated positron emission tomog-
aphy (PET)/CT with F-18 fluorodeoxyglucose (FDG) is a
efined type of dedicated FDG-PET that measures a stan-
ardized uptake value (SUV). This is an increasingly useful
oninvasive imaging modality with which to evaluate inde-
erminate lung nodules, regional lymph nodes, distant me-
astases, tumor invasiveness, and responses to chemoradio-
herapy.6-14 Furthermore, FDG-PET/CT might be able to
uantify the aggressiveness of small adenocarcinomas.
Notably, preoperative imaging findings with PET/CT
nd HR-CT must be defined and correlated with pathologic
ndings. Understanding the biologic features of small ade-
ocarcinomas preoperatively could provide clues to select
atients for radical sublobar resection. We therefore exam-
ned correlations between SUV, GGO proportion, and TDR
ith the BAC proportion defined on pathologic sections of
urgical specimens. The results of this study could improve
pproaches to diagnosing and treating small lung adenocar-
inomas that might become a more vital part of thoracic
Abbreviations and Acronyms
BAC  bronchioloalveolar carcinoma
CEA  serum carcinoembryonic antigen
GGO  ground-glass opacity
HR-CT high-resolution computed tomography
HU  Hounsfield units
maxD maximum dimensions of the tumors
perD  largest dimension perpendicular to the
maximum axis
PET  positron emission tomography
SUV  standardized uptake value
TDR  tumor shadow disappearance rateurgical tradition. l
The Journal of Thoracicaterials and Methods
etween October 2005 and September 2006, the same surgical
eam completely resected tumors and assessed ipsilateral hilar and
ediastinal lymph nodes for primary cT1N0M0 lung adenocarci-
omas (3 cm or less in diameter) in 60 consecutive patients. Our
nstitutional review board approved the prospective database used
n this retrospective analysis. Surgical–pathologic staging was
erformed according to the New International Staging System for
ung Cancer.15 All patients underwent integrated FDG-PET/CT
nd HR-CT within 1 month before resection. Patients with diabetes
ere excluded from this study.
FDG-PET/CT scans were carried out on an integrated PET/CT
canner (Discovery ST8 PET/CT Scanner; General Electric, Mil-
aukee, Wis). Patients were requested to fast for 4 hours and then
ntravenously received 185 MBq (5 mCi) of FDG, followed by
ET scanning after 40 minutes. Iterative reconstruction with CT
ttenuation correction was performed. Also, chest CT scan was
vailable for visual correlation. Maximum SUV was established by
rawing regions of interest on attenuation-corrected FDG-PET
mages around the primary tumor and calculated by the software
ithin the PET/CT scanner using the following formula: Maxi-
um SUV  [C(Ci/mL)/ID(Ci)]/w, where C is defined as
ctivity at a pixel within the tissue identified by an regions of
nterest and ID is defined as the injected dose per kilogram of the
atient’s body weight (w). We adopted maximum SUV in the
resent analysis because it is less variable than mean SUV in
easuring16 and established a value of 2.5 g/mL or higher as
ositive.
Contrast-enhanced HR-CT was performed on a multidetector
T capable of generating 16  0.5–mm slices (Aquilion 16SH;
oshiba Medical Systems, Tokyo, Japan). Slices with 1-mm
paces were taken through the tumor in addition to all slices with
-mm spacing obtained from the apex of the lung to the base. The
mages were photographed using a window level of 600
ounsfield units (HU) with a window width of 1700 HU (lung
indows) and a level of 25 HU with a width of 350 HU (medi-
stinal windows). TDR and GGO were assessed by independent
bservers, and discrepancies in evaluation among them were re-
olved by averaging their determined values. The observers mea-
ured the maximum dimensions of the tumors (maxD) and the
argest dimension perpendicular to the maximum axis (perD) on
oth the lung and mediastinal windows. As reported else-
here,4,5,17 T D R w a s defined as follows: TDR(%)  [1  (maxD 
erD on mediastinal windows/maxD perD on lung windows)]
00.
The tumors resected surgically were fixed in 10% formalin and
mbedded in paraffin. The sections including the largest cut were
tained with hematoxylin–eosin and elastica van Gieson for his-
opathologic examination. The estimation regarding the proportion
f BAC areas relative to the whole tumors was performed by
ndependent pathologists in the same manner as that for PET/CT
nd HR-CT reviews. The clinical records of all patients were also
eviewed to determine age, gender, smoking status, serum carci-
oembryonic antigen (CEA) level, tumor size, operative proce-
ure, lymph node status, lymphatic invasion, and vascular inva-
ion. When lymphatic and blood vessels had been invaded,
denocarcinoma cells were histopathologically identifiable in the
ymphatic and blood vessel lumen, respectively. Lymphatic and
and Cardiovascular Surgery ● Volume 133, Number 6 1449
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1
G
TSlood vessels were identified based on morphology using light
icroscopy and elastica stain. Peritumoral invasion (observed
utside the margin of the invasive carcinoma) and intratumoral
ypes of invasion were assessed.
The associations between clinical factors and maximum SUV,
GO ratio, TDR, and BAC ratio were evaluated using the 2 test
r the Fisher exact tests. To elucidate variables for the prediction
f nodal, lymphatic, and vessel involvement, we performed logis-
ic regression analyses. To further clarify independent variables in
elation to the prediction of nodal involvement, we performed
ultiple logistic regression analyses using gender for category and
ge, CEA, maximum SUV, GGO ratio, TDR, and BAC ratio as
ontinuous variables. We also examined which of maximum SUV,
GO ratio, or TDR correlated more closely with the BAC ratio
sing a correlation coefficient.
esults
f 60 patients examined, 31 (52%) were women and 29
ere men. The mean age was 65 years (range 34–82 years).
hirty-one patients (52%) were smokers, of whom 17 cur-
ently smoked, and 29 had never smoked. Forty-eight pa-
ients (80%) had a normal preoperative CEA level, the
pper limit of which was 5.0 ng/mL. Half of the patients had
primary tumor with a diameter of 20 mm or less, and the
ther half had a tumor of 21 to 30 mm in diameter. Lobec-
omy was the most frequently applied type of resection (n
4, 73%), and 16 patients underwent segmental resections.
he reasons for sublobar resection included radical segmen-
ectomy for tumors 2 cm or smaller in 11 patients and
ABLE 1. Clinical characteristics of patients with cT1N0M0
denocarcinoma relative to the level of maximum SUV on
DG-PET/CT images
Maximum SUV
< 2.5 (n  39)
Maximum SUV
> 2.5 (n  21) P value
ge (y) (means  SD) 64.3  9.8 66.1  9.2 .4939
ender
Male 17 12 .4184
Female 22 9
moking status
Smoker 18 13 .2874
Nonsmoker 21 8
EA (ng/mL)
5 35 13 .0169
5 4 8
umor size (mm)
T  20 25 5 .0061
20  T  30 14 16
rocedure
Lobectomy 27 17 .3767
Segmentectomy 12 4
UV, Standardized uptake value; FDG-PET/CT, positron emission tomog-
aphy– computed tomography with F-18 fluorodeoxyglucose; SD, standard
eviation; CEA, carcinoembryonic antigen.ompromised reserve in 5. Pneumonectomy was never per- u
450 The Journal of Thoracic and Cardiovascular Surgery ● Junormed, and wedge resection was excluded because nodal
tatus could not be histopathologically confirmed. All pa-
ients had curative R0 resections. Lymphatic and vascular
nvasion occurred in 18 (30%) and 13 (22%) patients, re-
pectively. Fifty-two patients (87%) had no nodal involve-
ent, whereas hilar or mediastinal lymph node involvement
as found in 8 patients (13%).
The clinical features of the patients in relationship to
aximum SUV on PET/CT are summarized in Table 1.
arger tumors (P  .0061) and a high preoperative CEA
alue (P  .0169) were more frequent in patients with a
ositive maximum SUV. Maximum SUV did not differ with
ge, gender, smoking status, and operative procedure. The
EA value was frequently high in patients whose propor-
ions of GGO and TDR on HR-CT and pathologic BAC on
urgical specimen (Tables 2, 3, and 4) were below 50%
roportion (P  .0446, P  .0498, and P  .0253,
espectively).
We then analyzed the predictors for lymphatic invasion,
ascular invasion, and nodal metastasis (Table 5). Maxi-
um SUV, GGO proportion, TDR, and BAC proportion
ere all found to be significant predictors of lymphatic (P
0001, P  .0189, P  .0020, and P  .0005, respectively)
nd vascular (P  .0001, P  .0433, P  .0256, and P 
0001, respectively) invasion. Whereas maximum SUV,
DR, and BAC proportion were significant predictors of
odal metastasis (P  .0019, P  .0201, and P  .0053,
espectively), the GGO proportion was not significantly
ABLE 2. Clinical characteristics of patients with cT1N0M0
denocarcinoma relative to the proportion of GGO on HR-CT
mages
GGO > 50%
(n  20)
GGO < 50%
(n  40) P value
ge (y) (means  SD) 65.4  8.9 64.1  10.9 .6367
ender
Male 7 22 .1772
Female 13 18
moking status
Smoker 8 23 .2749
Nonsmoker 12 17
EA (ng/mL)
5 19 29 .0466
5 1 11
umor size (mm)
T  20 13 17 .1702
20  T  30 7 23
rocedure
Lobectomy 14 30 .7604
Segmentectomy 6 10
GO, Ground-glass opacity; HR-CT, high-resolution computed tomography;
D, standard deviation; CEA, carcinoembryonic antigen.seful for predicting nodal status (P  .2487). Overall,
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G
TSaximum SUV, BAC ratio, TDR, and the GGO ratio in that
rder can likely reflect tumor aggressiveness. A multivariate
nalysis to determine independent predictors of pathologic
odal status (Table 6) revealed that age, gender, and CEA
ere not significant in any model. Maximum SUV (P 
0199), TDR (P  .0136), and BAC ratio (P  .0375) were
ignificantly useful predictors of nodal status, although
GO ratio and nodal status correlated marginally but not
ignificantly (P  .0800).
Last, we performed logistic regression analyses to clarify
hich radiographic parameter of maximum SUV, GGO
atio, or TDR correlated better with a pathologic BAC ratio
Figure 1). Although a significant correlation was found
etween BAC ratio versus maximum SUV, GGO ratio, and
DR (all P  .0001), maximum SUV (R2  0.245) had a
oorer association with BAC ratio compared with GGO
atio (R2  0.554) and TDR (R2  0.671). These data
emonstrated that both TDR and GGO ratio on HR-CT
ere well correlated with pathologic BAC ratio and that
aximum SUV on PET/CT had a much lesser impact as a
reoperative indictor of pathologic BAC proportion.
iscussion
lthough the proportion of the BAC component can mirror
he malignant grade of small adenocarcinoma,4,18,19 it is
efined on postsurgical specimens. Because the parts indi-
ating GGO or TDR on HR-CT seemed to closely correlate
ith BAC area, the proportion of GGO and TDR might be
inked to tumor aggressiveness and subsequently to risk for
ABLE 3. Clinical characteristics of patients with cT1N0M0
denocarcinoma relative to TDR on HR-CT images
TDR > 50%
(n  32)
TDR < 50%
(n  28) P value
ge (y) (means  SD) 66.1  9.5 63.9  9.6 .3632
ender
Male 13 16 .3005
Female 19 12
moking status
Smoker 16 15 .8017
Nonsmoker 16 13
EA (ng/mL)
5 29 19 .0498
5 3 9
umor size (mm)
T  20 20 10 .0692
20  T  30 12 18
rocedure
Lobectomy 21 23 .2417
Segmentectomy 11 5
DR, Tumor shadow disappearance rate; HR-CT, high-resolution computed
omography; SD, standard deviation; CEA, carcinoembryonic antigen.odal metastases and survival.4,5,17 Characterizing and r
The Journal of Thoracicuantifying these findings on HR-CT, especially GGO, have
een relatively subjective as interobserver discrepancies
ight have affected visual estimations.
Cerfolio and colleagues11 reported that maximum SUV
f a non–small cell lung cancer nodule on dedicated PET is
n independent predictor of tumor characteristics for stage,
ecurrence, and survival. However, the utility of FDG-
ET/CT in predicting the biologic features of small adeno-
arcinomas, especially BACs, remains obscure. Although
pproximately 85% of non–small cell lung cancers are FDG
ositive, roughly 50% of adenocarcinomas with a BAC
omponent are FDG positive, and pure BAC is more likely
o escape detection with FDG-PET.20,21 Lower metabolic
ctivity in adenocarcinomas containing a BAC component
s assumed to be secondary to the slower pace of BAC
roliferation compared with other adenocarcinomas. If
igher metabolic activity is linked to more tumor aggres-
iveness, FDG avidity (maximum SUV) might identify a
roup of adenocarcinomas that is more likely to have high-
rade malignant behavior.
In the present series, adenocarcinoma with a high max-
mum SUV as well as a low percentage of GGO, TDR, or
AC was more frequently associated with an increase in the
erum CEA level. Presurgical serum CEA values are im-
ortant in identifying patients at high risk of potential ad-
anced disease and poor survival and whose specificity is
igher for adenocarcinoma than squamous cell carcino-
a.22,23 The present study also uncovered an even closer
ABLE 4. Clinical characteristics of patients with
T1N0M0 adenocarcinoma relative to the proportion of
AC on pathologic examination
BAC > 50%
(n  28)
BAC < 50%
(n  32) P value
ge (y) (means  SD) 65.4  10.9 64.5  8.4 .7305
ender
Male 10 19 .0773
Female 18 13
moking status
Smoker 12 19 .3005
Nonsmoker 16 13
EA (ng/mL)
5 26 22 .0253
5 2 10
umor size (mm)
T  20 18 12 .0692
20  T  30 10 20
rocedure
Lobectomy 20 24 .7780
Segmentectomy 8 8
AC, Bronchioloalveolar carcinoma; SD, standard deviation; CEA, carci-
oembryonic antigen.elationship between maximum SUV and lymphatic, blood
and Cardiovascular Surgery ● Volume 133, Number 6 1451
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1
G
TSessel, and lymph node involvement compared with GGO,
DR, and BAC. Surprisingly, maximum SUV obtained
reoperatively could be a more reliable indicator for pre-
icting tumor malignancy than BAC proportion obtained
ABLE 5. Univariate analysis of predictors for Ly factor, V
actors Favorable U
or Ly factor
Maximum SUV 2.5
GGO ratio 50
TDR 50
Pathologic BAC ratio 50
or V factor
Maximum SUV 2.5
GGO ratio 50
TDR 50
Pathologic BAC ratio 50
or N factor
Maximum SUV 2.5
GGO ratio 50
TDR 50
Pathologic BAC ratio 50
Y factor, Lymphatic invasion status; N factor, lymph node status; V factor, v
GO, ground-glass opacity; TDR, tumor shadow disappearance rate; BAC
ABLE 6. Logistic regression analysis of clinicopathologic
actors for positive predictive values of pathologic nodal
tatus
actors Odds ratio (95% CI) P value
odel 1 (R 2  0.146)
Age 0.960 (0.880-1.048) .3613
Gender 0.530 (0.086-3.279) .4948
CEA 0.999 (0.774-1.290) .9936
Maximum SUV 1.709 (1.088-2.684) .0199
odel 2 (R 2  0.136)
Age 0.949 (0.866-1.039) .2577
Gender 0.811 (0.164-4.021) .7977
CEA 1.026 (0.813-1.295) .8270
GGO ratio 0.961 (0.920-1.005) .0800
odel 3 (R 2  0.282)
Age 0.948 (0.858-1.047) .2925
Gender 0.858 (0.143-5.153) .8669
CEA 1.013 (0.751-1.367) .9334
TDR 0.937 (0.890-0.987) .0136
odel 4 (R 2  0.208)
Age 0.960 (0.869-1.061) .4247
Gender 0.589 (0.113-3.070) .5295
CEA 0.989 (0.776-1.261) .9312
Pathologic BAC ratio 0.958 (0.920-0.998) .0375
ategory for gender and continuous variables for age, CEA, maximum SUV,
GO ratio, TDR, and BAC ratio. CI, Confidence interval; CEA, carcinoem-
ryonic antigen; SUV, standardized uptake value; GGO, ground-glass opac-
ty; TDR, tumor shadow disappearance rate; BAC, bronchioloalveolar
earcinoma.
452 The Journal of Thoracic and Cardiovascular Surgery ● Junostoperatively. These results suggested that maximum
UV is a reasonable surrogate marker of adenocarcinoma
nvasiveness and that FDG-PET/CT could be a powerful
rognostic tool with which to identify patients at high and
ow risk of recurrence after complete resection of small
denocarcinomas with or without a BAC component.
The relationships between the pathologic BAC ratio and
adiographic maximum SUV, GGO ratio, and TDR in small
denocarcinomas are of interest in helping to understand the
undamental role of maximum SUV. The extent of both the
GO area and TDR closely correlated with that of BAC
rowth. However, we emphasize that maximum SUV, in
omparison with the GGO ratio and TDR, was less associ-
ted with the BAC proportion. This discrepancy can be
ssential when considering the underlying significance of
aximum SUV. That is, graphic maximum SUV, unlike the
GO ratio or TDR, is less able to reflect the pathologic
AC proportion and might be an imperative predictor for
he grade of tumor malignancy independently of the BAC
omponent.
The current relative decrease in the size of resected lung
umors allows a choice of various surgical options.2 Choos-
ng radical sublobar resection for patients who could toler-
te lobectomy requires better methods of preoperatively
istinguishing early, indolent from advanced, aggressive
ancers. However, no absolutely accurate preoperative in-
icators of tumor behavior have been defined, although
everal studies have reported that the GGO ratio and TDR
n HR-CT as well as tumor size and histology are
seful.3-5,17 Our series showed that maximum SUV on
ET/CT is a potentially promising parameter for determin-
ng an indication for radical sublobar resection. We also
or, and N factor status
rable Odds ratio (95% CI) P value
.5 17.50 (4.420-69.283) .0001
0 6.00 (1.221-9.481) .0189
0 7.00 (1.940-25.255) .0020
0 13.00 (2.634-64.163) .0005
.5 — .0001
0 8.142 (0.9759-67.947) .0433
0 5.37 (1.301-22.172) .0256
0 — .0001
.5 19.00 (2.141-168.660) .0019
0 4.03 (0.460-35.299) .2487
0 10.33 (1.183-90.260) .0201
0 — .0053
ar invasion status; CI, confidence interval; SUV, standardized uptake value;
chioloalveolar carcinoma.fact
nfavo
2
5
5
5
2
5
5
5
2
5
5
5
asculxamined the relationship between maximum SUV and
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The Journal of Thoracic
G
TSumor size in cT1N0M0 adenocarcinomas (Figure 2). We
ound that the larger the tumor, the higher the maximum
UV, and both of these factors can predict tumor invasive-
ess and nodal metastases. Thus, FDG-PET/CT in addition
o HR-CT, may be significantly useful for an indication of
adical sublobar resection and a reduction in nodal dissec-
ion for surgically treating small adenocarcinomas, which
equires further confirmation in a large cohort.
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